Vietnam Metabolic Disorder Drugs Market Analysis

Vietnam Metabolic Disorder Drugs Market Analysis


$ 3999

Vietnam metabolic disorder drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The ageing population, rising diabetes and obesity rates, and the prevalence of metabolic disorders are all driving factors for the global market for medications treating these conditions. Another element fueling the expansion of this market is an increase in public awareness of various ailments and associated pharmacological treatments. Some of the major key players in this market are AbbVie, Actelion Pharmaceuticals, Amgen, Astra Zeneca, Biocon, BioMarin Pharmaceutical, etc.

ID: IN10VNPH334 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Vidhi Upadhyay

Buy Now

Vietnam Metabolic Disorder Drugs Market Analysis Summary

Vietnam Metabolic Disorder Drugs Market is valued at around $785.2 Mn in 2022 and is projected to reach $978.5 Mn by 2030, exhibiting a CAGR of 2.79% during the forecast period 2023-2030.

A metabolic problem impairs how the body distributes and processes macronutrients like proteins, lipids, and carbs. When the body's regular metabolic function is impacted by aberrant chemical interactions, metabolic diseases can result. The increase in sedentary employment, hectic lifestyles, and changing consumer preferences are all affecting the sickness profile of the world's population, especially non-communicable diseases like diabetes and obesity. Long work hours, a lack of exercise, and poor eating and drinking habits are the main causes of metabolic illnesses.

According to the World Health Organization (WHO), the frequency of chronic diseases is expected to rise by 57 percent worldwide by 2020. These factors are expected to increase the number of patients worldwide, driving the market for medications that treat metabolic disorders over the forecast timeframe. The ageing population, rising diabetes, and obesity rates, and the prevalence of metabolic disorders are all driving factors for the global market for medications treating these conditions. Another element fueling the expansion of this market is an increase in public awareness of various ailments and associated pharmacological treatments. The major key players in this market are AbbVie, Actelion Pharmaceuticals, Amgen, Astra Zeneca, Biocon, BioMarin Pharmaceutical, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla, CymaBay Therapeutics, Eli Lilly, Fuji Yakuhin, KOWA, Kythera, LG Life Science, Merck, Mitsubishi Tanabe Pharma, Novartis, Novo Nordisk, Sanofi, Shire PLC, Takeda Pharmaceutical.

Market Dynamics

Market Growth Drivers

The global market for pharmaceuticals treating these ailments is being driven by the ageing population, rising diabetes and obesity rates, and the incidence of metabolic disorders. An additional factor driving the growth of this industry is a rise in public awareness of various illnesses and the pharmaceutical therapies linked to them. Additionally, new market opportunities are projected as a result of the rising uses for drugs that treat metabolic illnesses and their advantages over complementary therapies.

Market Restraints

One of the primary reasons limiting the growth of the global market for drugs that treat metabolism is clinical holds on trials by industry participants. The FDA, for instance, put the FORTIS Phase 1/2 experiment on clinical hold as a result of a serious adverse event (SAE) of peripheral sensory neuropathy happening in one of the trial participants, according to a June 26, 2022 report from the pharmaceutical company Astellas Pharma Inc. As part of the Fortis Clinical Trial, adults with Late-Onset Pompe Disease are receiving treatment with AT845, an investigational adeno-associated virus (AAV) gene replacement therapy.

Competitive Landscape

Key Players

  • AbbVie
  • Actelion Pharmaceuticals
  • Amgen
  • Astra Zeneca
  • Biocon
  • BioMarin Pharmaceutical
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cipla
  • CymaBay Therapeutic
  • Eli Lilly
  • Fuji Yakuhin
  • KOWA
  • Kythera
  • LG Life Science
  • Merck
  • Mitsubishi Tanabe Pharma
  • Novartis
  • Novo Nordisk
  • Sanofi
  • Shire PLC
  • Takeda Pharmaceutical

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Vietnam Metabolic Disorder Drugs Market Segmentation

By Therapy

  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others

By Applications

  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up